These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 34997451)

  • 21. An extent of resection threshold for recurrent glioblastoma and its risk for neurological morbidity.
    Oppenlander ME; Wolf AB; Snyder LA; Bina R; Wilson JR; Coons SW; Ashby LS; Brachman D; Nakaji P; Porter RW; Smith KA; Spetzler RF; Sanai N
    J Neurosurg; 2014 Apr; 120(4):846-53. PubMed ID: 24484232
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Repeat-surgery at Glioblastoma recurrence, when and why to operate?
    Ening G; Huynh MT; Schmieder K; Brenke C
    Clin Neurol Neurosurg; 2015 Sep; 136():89-94. PubMed ID: 26092644
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Reoperation for Recurrent Glioblastoma Multiforme.
    Robin AM; Lee I; Kalkanis SN
    Neurosurg Clin N Am; 2017 Jul; 28(3):407-428. PubMed ID: 28600015
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Second surgery for recurrent glioblastoma: A concise overview of the current literature.
    Montemurro N; Perrini P; Blanco MO; Vannozzi R
    Clin Neurol Neurosurg; 2016 Mar; 142():60-64. PubMed ID: 26811867
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Molecular characteristics and clinical features of multifocal glioblastoma.
    Dono A; Wang E; Lopez-Rivera V; Ramesh AV; Tandon N; Ballester LY; Esquenazi Y
    J Neurooncol; 2020 Jun; 148(2):389-397. PubMed ID: 32440969
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Resection of recurrent glioblastoma multiforme in elderly patients: a pseudo-randomized analysis revealed clinical benefit.
    Fariña Nuñez MT; Franco P; Cipriani D; Neidert N; Behringer SP; Mader I; Delev D; Fung C; Beck J; Sankowski R; Nicolay NH; Heiland DH; Schnell O
    J Neurooncol; 2020 Jan; 146(2):381-387. PubMed ID: 31933259
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Impact of extent of resection for recurrent glioblastoma on overall survival: clinical article.
    Bloch O; Han SJ; Cha S; Sun MZ; Aghi MK; McDermott MW; Berger MS; Parsa AT
    J Neurosurg; 2012 Dec; 117(6):1032-8. PubMed ID: 23039151
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The prognostic significance of CDKN2A homozygous deletion in IDH-mutant lower-grade glioma and glioblastoma: a systematic review of the contemporary literature.
    Lu VM; O'Connor KP; Shah AH; Eichberg DG; Luther EM; Komotar RJ; Ivan ME
    J Neurooncol; 2020 Jun; 148(2):221-229. PubMed ID: 32385699
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Complete resection of contrast-enhancing tumor volume is associated with improved survival in recurrent glioblastoma-results from the DIRECTOR trial.
    Suchorska B; Weller M; Tabatabai G; Senft C; Hau P; Sabel MC; Herrlinger U; Ketter R; Schlegel U; Marosi C; Reifenberger G; Wick W; Tonn JC; Wirsching HG
    Neuro Oncol; 2016 Apr; 18(4):549-56. PubMed ID: 26823503
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Impact of Early Reoperation on the Prognosis of Patients Operated on for Glioblastoma.
    Troya-Castilla M; Kaen A; Márquez-Rivas FJ; Infante-Cossio P; Rius Díaz F; Narros Gimenez JL; Gonzalez-Pombo M; Cancela P; Segura Fernández-Nogueras M; Arráez Sánchez MÁ
    World Neurosurg; 2020 Jul; 139():e592-e600. PubMed ID: 32330620
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Association of Maximal Extent of Resection of Contrast-Enhanced and Non-Contrast-Enhanced Tumor With Survival Within Molecular Subgroups of Patients With Newly Diagnosed Glioblastoma.
    Molinaro AM; Hervey-Jumper S; Morshed RA; Young J; Han SJ; Chunduru P; Zhang Y; Phillips JJ; Shai A; Lafontaine M; Crane J; Chandra A; Flanigan P; Jahangiri A; Cioffi G; Ostrom Q; Anderson JE; Badve C; Barnholtz-Sloan J; Sloan AE; Erickson BJ; Decker PA; Kosel ML; LaChance D; Eckel-Passow J; Jenkins R; Villanueva-Meyer J; Rice T; Wrensch M; Wiencke JK; Oberheim Bush NA; Taylor J; Butowski N; Prados M; Clarke J; Chang S; Chang E; Aghi M; Theodosopoulos P; McDermott M; Berger MS
    JAMA Oncol; 2020 Apr; 6(4):495-503. PubMed ID: 32027343
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Partial resection offers an overall survival benefit over biopsy in MGMT-unmethylated IDH-wildtype glioblastoma patients.
    Hallaert G; Pinson H; Vanhauwaert D; Van den Broecke C; Van Roost D; Boterberg T; Kalala JP
    Surg Oncol; 2020 Dec; 35():515-519. PubMed ID: 33152608
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Genetic, Epigenetic, and Immunologic Profiling of MMR-Deficient Relapsed Glioblastoma.
    Indraccolo S; Lombardi G; Fassan M; Pasqualini L; Giunco S; Marcato R; Gasparini A; Candiotto C; Nalio S; Fiduccia P; Fanelli GN; Pambuku A; Della Puppa A; D'Avella D; Bonaldi L; Gardiman MP; Bertorelle R; De Rossi A; Zagonel V
    Clin Cancer Res; 2019 Mar; 25(6):1828-1837. PubMed ID: 30514778
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Histopathological correlates with survival in reoperated glioblastomas.
    Woodworth GF; Garzon-Muvdi T; Ye X; Blakeley JO; Weingart JD; Burger PC
    J Neurooncol; 2013 Jul; 113(3):485-93. PubMed ID: 23666202
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Treatment Results for Recurrent Glioblastoma and Alteration of Programmed Death-Ligand 1 Expression After Recurrence.
    Sung KS; Roh TH; Moon JH; Kim EH; Kang SG; Kim SH; Chang JH
    World Neurosurg; 2020 Mar; 135():e459-e467. PubMed ID: 31843727
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Usefulness of Reintervention in Recurrent Glioblastoma: An Indispensable Weapon for Increasing Survival.
    Delgado-Fernandez J; Garcia-Pallero MÁ; Blasco G; Penanes JR; Gil-Simoes R; Pulido P; Sola RG
    World Neurosurg; 2017 Dec; 108():610-617. PubMed ID: 28939537
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Germline ALK variations are associated with a poor prognosis in glioma and IDH-wildtype glioblastoma.
    Bu L; Hameed NUF; Luo C; Hong P; Zhou X; Wang S; Wu S
    J Neurooncol; 2021 Mar; 152(1):27-36. PubMed ID: 33486679
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Survival after reoperation for recurrent glioblastoma.
    Woodroffe RW; Zanaty M; Soni N; Mott SL; Helland LC; Pasha A; Maley J; Dhungana N; Jones KA; Monga V; Greenlee JDW
    J Clin Neurosci; 2020 Mar; 73():118-124. PubMed ID: 31987636
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Stereotactic radiosurgery for IDH wild type glioblastoma: an international, multicenter study.
    Bunevicius A; Pikis S; Kondziolka D; Patel DN; Bernstein K; Sulman EP; Lee CC; Yang HC; Delabar V; Mathieu D; Cifarelli CP; Arsanious DE; Dahshan BA; Weir JS; Speckter H; Mota A; Tripathi M; Kumar N; Warnick RE; Peker S; Samanci Y; Barnett G; Hefnawi FE; Al Sideiri G; Sheehan J
    J Neurooncol; 2021 Dec; 155(3):343-351. PubMed ID: 34797526
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Is MGMT promoter methylation to be considered in the decision making for recurrent surgery in glioblastoma patients?
    Pala A; Schmitz AL; Knoll A; Schneider M; Hlavac M; König R; Wirtz CR; Coburger J
    Clin Neurol Neurosurg; 2018 Apr; 167():6-10. PubMed ID: 29425743
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.